Value through Innovation02 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

25.05.2012

Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media
23.05.2012

€100,000 in reward donations for projects fundraising to prevent atrial fibrillation-related strokes

- For NON-US Media Only
22.05.2012

One million signatures needed to call upon World Health Organisation to save lives through education and improved management of atrial fibrillation

- For NON-US Media Only
22.05.2012

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

- For Media outside the U.S., Canada and UK
21.05.2012

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

- For Media outside the U.S., Canada and UK
29.04.2012

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

- For Non-US and Non-UK Healthcare Media Only
24.04.2012

Boehringer Ingelheim on growth path - Successful 2011 financial year

20.04.2012

GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media
19.04.2012

Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)

- For media outside of the U.S.A. only
19.04.2012

First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate

- For media outside of the U.S.A. only
18.04.2012

Leading medical and patient organisations join forces to improve stroke prevention in atrial fibrillation

- For NON-US and NON-UK Media Only
18.04.2012

Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin

- For Non-US, UK & Canadia Media Only
16.03.2012

Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK1

- For NON-US, NON-UK & NON- Canadian Healthcare Media Only
12.03.2012

Boehringer Ingelheim sets up its first Asian Veterinary Research & Development Center in Shanghai

02.03.2012

Porcine circovirus research projects from France and Spain awarded

29.02.2012

Boehringer Ingelheim expands capabilities in biopharmaceutical process science

21.02.2012

Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies

03.02.2012

Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration